Tiotropium Respimat increases the risk of mortality: con Source: Eur Respir J 2013; 42: 590-593 Year: 2013
Increased risk of mortality in COPD patients using tiotropium respimat vs. tiotropium Handihaler Source: Annual Congress 2012 - Exacerbations of asthma and COPD: assessment, impact and novel treatments Year: 2012
Lung function indices for predicting mortality in COPD Source: Eur Respir J 2013; 42: 616-625 Year: 2013
Use of tiotropium Respimat versus HandiHaler and mortality in patients with COPD Source: Eur Respir J 2014; 43: 1816-1818 Year: 2014
Use of tiotropium Respimat versus HandiHaler and mortality in patients with COPD Source: Eur Respir J 2014; 43: 1818-1819 Year: 2014
Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD Source: Eur Respir J 2013; 42: 606-615 Year: 2013
One-year mortality associated with COPD treatment: A comparison of tiotropium and long-acting beta-2-agonists Source: International Congress 2014 – Prevalence of COPD and mortality from COPD Year: 2014
Efficacy in COPD patients of tiotropium administered via the Respimat® Soft MistÔ Inhaler (SMI) compared to HandiHaler® (HH) Source: Eur Respir J 2006; 28: Suppl. 50, 431s Year: 2006
Comparison of the pharmacokinetics and pharmacodynamics of once daily tiotropium Respimat® and tiotropium HandiHaler® in COPD patients Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013
Dose-response to tiotropium administered via the Respimat® Soft MistÔ Inhaler (SMI) to patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 318s Year: 2006
Late Breaking Abstract - COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020
Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Twice-daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010
LATE-BREAKING ABSTRACT: Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: The SHINE study Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases Year: 2012
Lung function efficacy of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Two 48-week studies Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Cost effectiveness of budesonide/formoterol vs fluticasone/salmeterol: Real-world effectiveness and safety in COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
AMPLIFY: efficacy of aclidinium vs tiotropium in COPD Source: International Congress 2018 – COPD management Year: 2018
Once-daily tiotropium and olodaterol fixed-dose combination via the respimat improves outcomes vs mono-components in COPD in two 1-year studies Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014